-+ 0.00%
-+ 0.00%
-+ 0.00%

Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate

Benzinga·10/29/2026 11:09:59
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses of $(0.94) per share from the same period last year.